GO
Loading...

Enter multiple symbols separated by commas

Amgen Inc

More

  • March 16- U.S. stocks rallied on Monday as the U.S. dollar eased back from its recent peak and worries eased about the timing of a Federal Reserve interest rate hike. The S&P healthcare sector led gains in the S&P 500. It jumped 2.2 percent, helped by a 5.7 percent price increase in shares of Amgen to $163.03, following promising data in studies of a new class of...

  • "It's just a little bit of relief from last week's selloff," said Joseph Benanti, managing director, sales and trading of Rosenblatt Securities in New York. The S&P healthcare sector was up 1.9 percent, helped by a 3.6 percent price increase in shares of Amgen to $159.73, following promising data in studies of a new class of cholesterol-reducing drugs.

  • *Empire State manufacturing data miss estimates. "It's just a little bit of relief from last week's selloff," said Joseph Benanti, managing director, sales and trading of Rosenblatt Securities in New York. Until Fed Chair Janet Yellen's statement on Wednesday afternoon, Benanti is expecting light volume.

  • New cholesterol drugs cut heart attack risk in half Monday, 16 Mar 2015 | 8:44 AM ET
    Amgen

    Studies of a new class of cholesterol-lowering drugs signal that they can reduce by half the risk of heart attack.

  • An analysis of about 4,500 patients who stayed on treatment for nearly a year after completing earlier trials of Amgen Inc's Repatha, also known as evolocumab, found that 0.95 percent of those given the drug and standard therapy suffered a cardiovascular event, compared with 2.18 percent of the group on standard treatment, which ranged from diet changes to...

  • An analysis of about 4,500 patients who continued treatment for nearly a year after completing earlier trials of Amgen Inc's Repatha, also known as evolocumab, found that 0.95 percent of patients given the drug and standard therapy suffered a cardiovascular event, compared with 2.18 percent of the group receiving standard treatment, which ranged from...

  • These cholesterol drugs stocks are poised to move Friday, 13 Mar 2015 | 3:33 PM ET
    Surgeons performing operation

    Here are the stocks to watch heading out of this weekend's American College of Cardiology conference in San Diego.

  • CVS: Copycat drugs may bring price cuts of 40-50% Thursday, 12 Mar 2015 | 7:14 AM ET

    Copycat biotech drugs in the U.S. market could cut prices of expensive medications by 40 percent to 50 percent, said a top CVS Health exec.

  • WASHINGTON, March 11- The entry of copycat biotech drugs into the U.S. market could cut prices of expensive medications by 40 percent to 50 percent, depending on the level of competition among drugmakers, a top executive at CVS Health Corp told Reuters. CVS is one of the largest U.S. pharmacy benefit managers and, along with rival Express Scripts, has put...

  • In a letter released on Wednesday, the organization urged Health and Human Services Secretary Sylvia Burwell to withdraw the proposal, saying pharmaceutical companies could "sell more drugs by making them seem safer than FDA has judged them to be." The FDA said it would allow distribution of new information in medical journals showing that the severity or...

  • What!?! Specialty drug spending jumps 31% Tuesday, 10 Mar 2015 | 8:53 AM ET
    Prescription drugs

    Spending on prescription drugs in the U.S. rose 13.1% in 2014, the biggest increase in more than a decade, according a report from Express Scripts.

  • *Zarxio from Novartis generics unit Sandoz approved by FDA. *Copy of Amgen's white cell-boosting medicine Neupogen. The move had been expected after Zarxio, which is made by Novartis' generics unit Sandoz, won unanimous backing from an FDA panel in January.

  • *FDA set to decide on approval of Novartis' Zarxio. LONDON/ LOS ANGELES, March 6- A revolution is brewing in healthcare with lower-cost copies of complex biotech drugs finally set to reach the United States, nine years after so-called biosimilars were launched in Europe. The first approval for a biosimilar in the United States is expected imminently- Zarxio,...

  • 13 stocks that beat Warren Buffett Tuesday, 3 Mar 2015 | 8:16 AM ET
    Cleveland Cavaliers' LeBron James sits on the base line in front of Warren Buffett, left, in an NBA basketball game against the Charlotte Hornets Monday, Dec. 15, 2014, in Cleveland.

    These 13 stocks have beat the growth of Berkshire Hathaway in the years since 1985. USA Today reports.

  • Amgen cancer drug Kyprolis shows strength in study Monday, 2 Mar 2015 | 4:30 PM ET
    Amgen

    Amgen's EVP of Research and Development, Dr. Sean Harper, talks about their latest cancer drug, Kyprolis.

  • Cancer drug shows promise   Monday, 2 Mar 2015 | 1:17 PM ET
    Cancer drug shows promise

    Amgen's cancer drug Kyprolis demonstrated positive results in a study against Takeda's Velcade. Dr. Sean Harper, Amgen, discusses the benefit risk equation for both drugs.

  • Cramer: We're in a bubble. So, what? Apple's cheap Monday, 23 Feb 2015 | 6:19 PM ET

    The market is reaching new highs, but could we really be in a bubble? Jim Cramer finds out.

  • Feb 17- CVS Health on Monday warned that costs of a potent new class of cholesterol treatments and other specialty drugs in development could eclipse those of expensive new medicines and overwhelm the healthcare system "if rigid cost control mechanisms are not put in place." CVS' call for cost controls follows sharp criticism from insurers, other payers and...

  • Lightning Round: Charts are lining up for this group Wednesday, 11 Feb 2015 | 6:55 PM ET
    Mad Money Lightning Round

    Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Feb 5- Drugmaker Pfizer Inc said it would buy Hospira Inc for about $15 billion to boost its portfolio of generic injectible drugs and biosimilars, or copies of biotech drugs. Pfizer offered $90 per share in cash, a 39 percent premium to Hospira's closing stock price on Wednesday. Hospira soared 35 percent to near $88 before the bell Thursday, while Pfizer was up 3.6...